This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Actelion Pharmaceuticals Ltd. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Alexandra Schlicker-Spain: Innovator in Pharmaceutical Compositions
Introduction
Alexandra Schlicker-Spain is a notable inventor based in Allschwil, Switzerland. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions for medical use. Her work focuses on enhancing the efficacy and safety of pharmaceutical formulations.
Latest Patents
Alexandra holds a patent for a pharmaceutical composition comprising selexipag. This invention relates to aqueous pharmaceutical compositions that include the compound 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl) acetamide, glycine, polysorbate 20, and an aqueous phosphate buffer. The relative amounts of these components are specified in the patent description, with the pH of the composition maintained between about 7 and 8. Additionally, the patent covers lyophilized pharmaceutical compositions prepared from these aqueous compositions, as well as their reconstituted forms suitable for intravenous administration. The invention also details processes for preparing these compositions and their applications in treating diseases related to IP receptors.
Career Highlights
Alexandra is currently associated with Actelion Pharmaceuticals Ltd., where she continues to advance her research and development efforts. Her work has been instrumental in creating effective pharmaceutical solutions that address critical health issues.
Collaborations
Alexandra collaborates with various professionals in her field, including her coworker Klaus Hellerbrand. Their combined expertise contributes to the innovative projects at Actelion Pharmaceuticals Ltd.
Conclusion
Alexandra Schlicker-Spain exemplifies the spirit of innovation in the pharmaceutical industry. Her contributions through her patent and ongoing work at Actelion Pharmaceuticals Ltd. highlight her commitment to improving healthcare solutions.